Literature DB >> 6880856

Altered prednisolone pharmacokinetics in patients treated with rifampicin.

H Bergrem, O K Refvem.   

Abstract

The pharmacokinetics and protein binding of prednisolone were studied in 7 patients before and after 3 weeks of rifampicin therapy. The elimination half-time for prednisolone decreased by 45 +/- 8.1% (p less than 0.01), and the total body clearance of prednisolone increased by 91 +/- 26% (p less than 0.01). The area under the time-concentration curve (AUC) of total (free plus protein-bound) prednisolone decreased by 48 +/- 7.3% (p less than 0.01) and of free, unbound prednisolone by 57 +/- 9.8% (p less than 0.01). The reduction in AUC was greater for free than for total prednisolone (p less than 0.05) mainly due to the non-linear nature of prednisolone protein binding. There was no significant change in the volume of distribution. Because of the marked reduction in total and especially free prednisolone, the dosage should be adjusted accordingly if prednisolone and rifampicin are prescribed concomitantly.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6880856     DOI: 10.1111/j.0954-6820.1983.tb03748.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  9 in total

Review 1.  Clinical pharmacokinetics of prednisone and prednisolone.

Authors:  B M Frey; F J Frey
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

2.  Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin.

Authors:  K H Lee; J G Shin; W S Chong; S Kim; J S Lee; I J Jang; S G Shin
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 3.  Pharmacokinetic drug interactions with rifampicin.

Authors:  K Venkatesan
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

4.  Baffling Case of a Patient With History of Lupus in a COVID-19 Pandemic.

Authors:  Anum Qureshi; Kia Persaud; Fatima Halilu; Ji Hyun Rhee
Journal:  J Community Hosp Intern Med Perspect       Date:  2022-07-04

Review 5.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of the antituberculosis drugs.

Authors:  M R Holdiness
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

7.  Corticosteroid effects on sputum culture in pulmonary tuberculosis: a meta-regression analysis.

Authors:  Robert S Wallis
Journal:  Open Forum Infect Dis       Date:  2014-06-03       Impact factor: 3.835

Review 8.  Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management.

Authors:  Sasha R Fehily; Aysha H Al-Ani; Jonathan Abdelmalak; Clarissa Rentch; Eva Zhang; Justin T Denholm; Douglas Johnson; Siew C Ng; Vishal Sharma; David T Rubin; Peter R Gibson; Britt Christensen
Journal:  Aliment Pharmacol Ther       Date:  2022-05-20       Impact factor: 9.524

Review 9.  Corticosteroids as an adjunct to tuberculosis therapy.

Authors:  Charlotte Schutz; Angharad G Davis; Bianca Sossen; Rachel P-J Lai; Mpiko Ntsekhe; Yolande Xr Harley; Robert J Wilkinson
Journal:  Expert Rev Respir Med       Date:  2018-09-06       Impact factor: 3.772

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.